Delivery Order SPE2DB24D2011-SPE2DB25FBPYC

Award Date 2/4/25
Potential Completion Date 2/26/25
Potential Value $7.6K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,845.85 Firm Fixed Price delivery order is for the supply of NUBEQA 300 MG TABLET 120S, a specialty pharmaceutical product. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $9,691.72 firm fixed-price delivery order is for the supply of NUBEQA 300 MG tablets, a pharmaceutical product. The award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 between AmerisourceBergen and the DLA Troop Support Medical, which serves as a comprehensive vehicle for providing...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,641.98 firm fixed-price delivery order is for the supply of NUBEQA 300 MG TABLET 120S, with a completion date of February 12, 2025. The contract is not designated with a set-aside requirement. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,641.98 firm fixed-price delivery order contract is for the supply of NUBEQA 300 MG TABLET 120S, a pharmaceutical product. The contract has a performance period ending on February 19, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $9,691.72 firm fixed-price delivery order is for the supply of 120 count tablets of the pharmaceutical product NUBEQA 300 MG. The contract has a completion date of December 11, 2024 and was awarded on November 19, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,683.97 firm fixed-price delivery order is for the supply of NUBEQA 300 MG tablets, a prescription medication. This order is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,845.85 firm fixed-price delivery order is for the supply of 120 tablets of the medication NUBEQA 300 MG. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $4,845.85 firm fixed-price delivery order is for the supply of 120 tablets of the drug NUBEQA 300 MG. The award does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical through November 2026, which serves as a primary...
This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA). The $7,641.98 firm-fixed-price delivery order is for the supply of NUBEQA 300 MG TABLET 120S, a drug product, with a period of performance through February 2025. The award is not designated as a set-aside contract. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
The U.S. Defense Logistics Agency (DLA) awarded Amerisourcebergen Drug Corp, through its Corporate Office division, a delivery order contract valued at $3,518.40 for the supply of NUBEQA 300 MG TABLET 120S. This order is part of a larger Indefinite Delivery Contract (IDC) worth up to $999,999,999.00 held by Amerisourcebergen with the DLA Troop Support Medical, which serves as the primary vehicle for the company to deliver a wide range of pharmaceutical products and medical supplies to DLA...
  • SPE2DB24D2011
    Indefinite Delivery Contract
  • SPE2DB24D2011-SPE2DB25FBPYC
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,641.98 firm fixed-price delivery order is for the supply of NUBEQA 300 MG TABLET 120S, a pharmaceutical product. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract has no set-aside designation, indicating open competition. This contract supports the DLA's mission of providing medical commodities, including specialty medications, brand-name and generic drugs, vaccines, syringes, vials, and test kits, to military treatment facilities, veterans' healthcare programs, and other federal medical institutions.

Generated 5/6/25, 10:53 AM